ClinicalTrials.gg

Endometrial Neoplasms clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,428 studies for Endometrial Neoplasms across more than 10 countries. 472 are recruiting or about to start. 775 of them are mainly about Endometrial Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 2 narrower conditions too, such as Carcinoma, Endometrioid: 1,472 studies, 476 open.

ClinicalTrials.gov finds 1,669 studies for Endometrial Neoplasms. How that becomes 1,428 here

This page counts the studies the registry files under Endometrial Neoplasms, and those it files under no condition that list Endometrial Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 17, 2026. How condition pages count

  1. 1,669Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −36Filed under a narrower condition, counted on its own pageCarcinoma, Endometrioid 14 · Sarcoma, Endometrial Stromal 9
  3. −16List Endometrial Neoplasms as a condition, but the registry did not file them under itMost often written as “Advanced Endometrial Carcinoma” (2), “Early Stage Endometrial Cancer” (1), and “Microsatellite Instability (MSI)-High Endometrial Cancer” (1). The registry filed them under other conditions only, most often Ovarian Neoplasms (5) and Recurrence (4).
  4. −191Match it another way86 name it in the title, 2 in a keyword, and 103 by a synonym or other text the search reads.
  5. 1,426Counted here and found by its search26 of them list Endometrial Neoplasms in their own words; the registry filed them under no condition.
  6. +2
    Counted here, but its search does not find them
  7. 1,428The count on this page

Status

Completed
523
Recruiting
356
Status unknown
146
Active, not recruiting
135
Not yet recruiting
109
Terminated
104

Phase

Phase 2
444
Phase 1
326
Phase 3
94
Early Phase 1
24
Phase 4
14

Where

United States
715
China
170
Italy
139
Spain
130
Canada
128
France
125

Who develops what

Add Endometrial Neoplasms to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 78 programs from 60 companies, 23 with this as their studies’ main aim; 11 with a live phase 3 study; 15 primary completions in the next 12 months. Compare AstraZeneca, GlaxoSmithKline and Eli Lilly here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
PaclitaxelRecent, repeated
Evidence
  • NCT07902999 · Shanghai Huaota Biopharmaceutical Co., Ltd. · Phase 3 · live · background · “Paclitaxel injection” · registered Oct 2026
  • NCT07652515 · GlaxoSmithKline · Phase 4 · live · background · “Paclitaxel” · registered Jun 2026
  • NCT07286331 · GlaxoSmithKline · Phase 3 · live · comparator · “Paclitaxel” · registered Dec 2025
  • NCT07044336 · AstraZeneca · Phase 3 · live · comparator · “Paclitaxel” · registered Jun 2025
  • NCT06952504 · Merck & Co., Inc · Phase 3 · live · background · “Paclitaxel” · registered Apr 2025
Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed1216 studies
CarboplatinRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07902999 · Shanghai Huaota Biopharmaceutical Co., Ltd. · Phase 3 · live · background · “Carboplatin injection” · registered Oct 2026
  • NCT07652515 · GlaxoSmithKline · Phase 4 · live · background · “Carboplatin” · registered Jun 2026
  • NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Carboplatin + Pemetrexed + Pembrolizumab” · registered May 2025
  • NCT06952504 · Merck & Co., Inc · Phase 3 · live · background · “Carboplatin” · registered Apr 2025
  • NCT06989112 · AstraZeneca · Phase 3 · live · comparator · “Carboplatin” · registered Mar 2025
Eli Lilly and Company16% of its industry studies1114 studies
DoxorubicinRecent, repeated
Evidence
  • NCT07286331 · GlaxoSmithKline · Phase 3 · live · comparator · “Doxorubicin” · registered Dec 2025
  • NCT07044336 · AstraZeneca · Phase 3 · live · comparator · “Doxorubicin” · registered Jun 2025
  • NCT06584032 · HUTCHMED · Phase 3 · live · comparator · “doxorubicin” · registered Aug 2024
  • NCT06486441 · Gilead Sciences · Phase 3 · live · comparator · “Doxorubicin” · registered Jun 2024
  • NCT06340568 · BioNTech SE · Phase 3 · live · comparator · “Doxorubicin” · registered Mar 2024
Hoffmann-La Roche10% of its industry studiesUS: off-patent, 14 generics marketed77 studies
pembrolizumabRecent, repeated
Evidence
  • NCT07684599 · GlaxoSmithKline · Phase 3 · live · background · “Pembrolizumab” · registered Jun 2026
  • NCT07578649 · Pfizer · Phase 3 · live · comparator · “Pembrolizumab” · registered May 2026
  • NCT07054567 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Pembrolizumab” · registered Jun 2025
  • NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Carboplatin + Pemetrexed + Pembrolizumab” · registered May 2025
  • NCT06989112 · AstraZeneca · Phase 3 · live · comparator · “Pembrolizumab” · registered Mar 2025
Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015)68 studies
DocetaxelRecent, repeated
Evidence
  • NCT06952504 · Merck & Co., Inc · Phase 3 · live · background · “Docetaxel” · registered Apr 2025
  • NCT06989112 · AstraZeneca · Phase 3 · live · comparator · “Docetaxel” · registered Mar 2025
  • NCT06340568 · BioNTech SE · Phase 3 · live · comparator · “Docetaxel” · registered Mar 2024
  • NCT05592626 · Marengo Therapeutics, Inc. · Phase 2 · live · background · “Docetaxel (Taxotere)” · registered Oct 2022
  • NCT05481645 · Sino Biopharmaceutical Limited · Phase 2 · background · “Docetaxel injection” · registered Jul 2022
Sanofi27% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 2 generics authorized67 studies
FulvestrantRecent, repeated
Evidence
  • NCT07811232 · Advenchen Pharmaceuticals, LLC. · Phase 2 · live · background · “Fulvestrant” · registered Aug 2026
  • NCT07109726 · Terremoto Biosciences Inc. · Phase 2 · live · background · “Fulvestrant injection” · registered Jul 2025
  • NCT06993844 · Ensem Therapeutics · Phase 2 · live · background · “ETX-636 dose escalation in combination with fulvestrant” · registered May 2025
  • NCT05867251 · Avenzo Therapeutics, Inc. · Phase 2 · live · background · “Fulvestrant” · registered Apr 2023
  • NCT05768139 · Eli Lilly and Company · Phase 2 · live · background · “Fulvestrant” · registered Mar 2023
AstraZeneca70% of its industry studiesUS: off-patent, 11 generics marketedEU: off-patent, 1 generic authorized55 studies
BevacizumabRecent, repeated
Evidence
  • NCT07054567 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Bevacizumab” · registered Jun 2025
  • NCT05919264 · Parabilis Medicines, Inc. · Phase 2 · live · background · “Bevacizumab” · registered May 2023
  • NCT05797168 · AstraZeneca · Phase 2 · live · background · “Bevacizumab” · registered Feb 2023
  • NCT05579366 · Genmab · Phase 2 · live · background · “Bevacizumab” · registered Oct 2022
  • NCT05489211 · AstraZeneca · Phase 2 · live · background · “Bevacizumab” · registered Jul 2022
Hoffmann-La Roche48% of its industry studiesUS: Hoffmann-La Roche (FDA 2004) + 6 othersEU: Hoffmann-La Roche (EMA 2005) + 7 others45 studies
Albumin-Bound PaclitaxelRecent, repeated
Evidence
  • NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Gemcitabine + Nab-paclitaxel” · registered May 2025
  • NCT06906341 · Corcept Therapeutics · Phase 2 · live · background · “Nab-paclitaxel 80 mg/m^2” · registered Apr 2025
  • NCT06132958 · Merck & Co., Inc · Phase 3 · live · comparator · “Nab-paclitaxel” · registered Nov 2023
  • NCT05383482 · Laekna Limited · Phase 2 · background · “Nab paclitaxel” · registered Apr 2022
Bristol-Myers Squibb43% of its industry studiesEU: Bristol-Myers Squibb (EMA 2008)44 studies
LetrozoleRecent, repeated
Evidence
  • NCT05867251 · Avenzo Therapeutics, Inc. · Phase 2 · live · background · “Letrozole” · registered Apr 2023
  • NCT05768139 · Eli Lilly and Company · Phase 2 · live · background · “Letrozole” · registered Mar 2023
  • NCT05705505 · Traws Pharma, Inc. · Phase 2 · live · background · “Letrozole 2.5mg” · registered Jan 2023
  • NCT05712941 · EQRx International, Inc. · Phase 3 · background · “Letrozole 2.5mg” · registered Oct 2022
Novartis52% of its industry studiesUS: off-patent, 6 generics marketed44 studies
GemcitabineRecent, repeated
Evidence
  • NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Gemcitabine + Nab-paclitaxel” · registered May 2025
  • NCT05548296 · Acrivon Therapeutics · Phase 2 · live · background · “Gemcitabine” · registered Aug 2022
  • NCT05481645 · Sino Biopharmaceutical Limited · Phase 2 · background · “Gemcitabine Hydrochloride Injection” · registered Jul 2022
  • NCT05007106 · Merck & Co., Inc · Phase 2 · background · “Gemcitabine” · registered Aug 2021
  • NCT04657068 · Artios Pharma Ltd · Phase 2 · live · background · “Gemcitabine” · registered Dec 2020
Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed33 studies
CisplatinRecent, repeated
Evidence
  • NCT06952504 · Merck & Co., Inc · Phase 3 · live · background · “Cisplatin” · registered Apr 2025
  • NCT05489211 · AstraZeneca · Phase 2 · live · background · “Cisplatin” · registered Jul 2022
  • NCT05173987 · Merck & Co., Inc · Phase 3 · live · comparator · “cisplatin” · registered Dec 2021
  • NCT05007106 · Merck & Co., Inc · Phase 2 · background · “Cisplatin” · registered Aug 2021
  • NCT04634877 · Merck & Co., Inc · Phase 3 · live · background · “Cisplatin” · registered Nov 2020
Eli Lilly and Company28% of its industry studiesUS: off-patent, 6 generics marketed23 studies
Antineoplastic AgentsRecent, repeated
Evidence
  • NCT07022483 · Daiichi Sankyo · Phase 3 · live · comparator · “Chemotherapy” · registered Jun 2025
  • NCT06475599 · Sino Biopharmaceutical Limited · Phase 3 · live · comparator · “Chemotherapy drug” · registered Jun 2024
  • NCT00739830 · Merck & Co., Inc · Phase 2 · comparator · “chemotherapy” · registered Aug 2008
—22 studies
PemetrexedRecent, repeated
Evidence
  • NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Carboplatin + Pemetrexed + Pembrolizumab” · registered May 2025
  • NCT06758557 · Huabo Biopharm Co., Ltd. · Phase 2 · live · background · “Pemetrexed” · registered Jan 2025
Eli Lilly and Company67% of its industry studiesUS: off-patent, 4 generics marketedEU: off-patent, 3 generics authorized22 studies
palbociclibRecent, repeated
Evidence
  • NCT05867251 · Avenzo Therapeutics, Inc. · Phase 2 · live · background · “Palbociclib” · registered Apr 2023
  • NCT05768139 · Eli Lilly and Company · Phase 2 · live · background · “Palbociclib” · registered Mar 2023
Pfizer81% of its industry studiesUS: Pfizer (FDA 2015)EU: off-patent, 1 generic authorized22 studies
ribociclibRecent, repeated
Evidence
  • NCT05867251 · Avenzo Therapeutics, Inc. · Phase 2 · live · background · “Ribociclib” · registered Apr 2023
  • NCT05768139 · Eli Lilly and Company · Phase 2 · live · background · “Ribociclib” · registered Mar 2023
Novartis87% of its industry studiesUS: Novartis (FDA 2017)EU: Novartis (EMA 2017)22 studies

30 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
puxitatug samrotecan☆ Track1 live phase-3 study: NCT07044336AstraZeneca
sacituzumab tirumotecan☆ Track2 live phase-3 studies: NCT06952504, NCT06132958Merck & Co., Inc
mocertatug rezetecan☆ Track2 live phase-3 studies: NCT07286331, NCT07684599GlaxoSmithKline
durvalumabApproved: US 2017 · EU 2018☆ Track2 live phase-3 studies: NCT04269200, NCT06746116AstraZeneca
trastuzumab deruxtecanApproved: US 2019 · EU 2021☆ Track1 live phase-3 study: NCT06989112AstraZeneca

The 5 in phase 3 with the nearest primary completion, of 78 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (15)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.izalontamab brengitecan · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 registry mapping onlyNCT05803018 A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies — primary endpoint: Phase Ib: Recommended Phase II Dose (RP2D) · 38 enrolled
  • 14 Dec 2026 est.dostarlimab · GlaxoSmithKline · Phase 2 named, not the main aimNCT06317311 A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer — primary endpoint: Durable response rate for 12 months (DRR12) assessed by Blinded independent central review (BICR) · 41 enrolled
  • 15 Dec 2026 est.Anti-IGSF8 Monoclonal Antibody GV20-0251 · GV20 Therapeutics · Phase 2 named, not the main aimNCT05669430 A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies — primary endpoint: Objective Response Rate ORR per RECIST version 1.1 (Parts B and D) · 365 enrolled

12 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Endometrial Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 41 open · Tyrosine kinase inhibitors (TKIs) 13 open · Antibody-drug conjugates (ADCs) 10 open · PARP inhibitors 9 open · Antimitotic agents 8 open

Coming up

165studies finish main data collection within a year6 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger. 26 (7%) take children under 18. 222 (62%) are for women only and 0 (0%) for men only; 23 (6%) take healthy volunteers.

Recruiting studies that take each age, of 356
AgeWomenMen
1019 (5%)8 (2%)
18328 (92%)128 (36%)
30343 (96%)131 (37%)
40345 (97%)132 (37%)
50331 (93%)131 (37%)
65333 (94%)132 (37%)
75327 (92%)131 (37%)
85290 (81%)121 (34%)

Across all 1,428 studies, recruiting or not: 12% stop at 75 or younger and 5% at 65; 11% take children; 69% are for women only and 0% for men only; 8% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Endometrial Neoplasms studies take

Of 139 phase 2 interventional studies under Endometrial Neoplasms, half reached primary completion within 55 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 161 mo46–79 · 131 studies54 mo45–69 · 88 studies67 mo53–80 · 43 studies
Phase 1/269 mo54–106 · 80 studies——
Phase 255 mo37–115 · 139 studies—60 mo40–115 · 107 studies
Phase 353 mo45–126 · 44 studies——
Interventional, no phase43 mo19–76 · 200 studies—44 mo20–76 · 194 studies
Observational105 mo32–206 · 150 studies—66 mo31–206 · 130 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Stopped1

Newly registered13

Show 8 more

Studies

Recruiting first, then most recently updated. Showing 50 of 1,428. Browse all 1,428 → or search them.